MCID: LKM070
MIFTS: 57

Leukemia, Acute Monocytic

Categories: Blood diseases, Cancer diseases, Immune diseases

Aliases & Classifications for Leukemia, Acute Monocytic

MalaCards integrated aliases for Leukemia, Acute Monocytic:

Name: Leukemia, Acute Monocytic 57 38
Acute Monocytic Leukemia 38 12 76 29 55 15 73
Acute Monoblastic Leukemia and Acute Monocytic Leukemia 12
Acute Monocytic Leukemia Without Mention of Remission 12
M5b Acute Differentiated Monocytic Leukemia 73
Acute Monocytic Leukemia, Morphology 12
Acute Monocytic Leukemia, Fab M5 12
Leukemia, Monocytic, Acute 44

Characteristics:

OMIM:

57
Inheritance:
autosomal dominant somatic cell mutation


HPO:

32
leukemia, acute monocytic:
Inheritance autosomal dominant somatic cell mutation


Classifications:



External Ids:

OMIM 57 151380
Disease Ontology 12 DOID:8864
ICD9CM 35 206.0
MeSH 44 D007948
SNOMED-CT 68 22331004 91859000
MedGen 42 C0023465
SNOMED-CT via HPO 69 413441006

Summaries for Leukemia, Acute Monocytic

Disease Ontology : 12 A monocytic leukemia where the majority of monocytic cells are promonocytes.

MalaCards based summary : Leukemia, Acute Monocytic, also known as acute monocytic leukemia, is related to monocytic leukemia and acute myeloid leukemia with abnormal bone marrow eosinophils inv(16)(p13q22) or t(16;16)(p13;q22). An important gene associated with Leukemia, Acute Monocytic is MALAT1 (Metastasis Associated Lung Adenocarcinoma Transcript 1), and among its related pathways/superpathways are cAMP signaling pathway and Tuberculosis. The drugs Busulfan and Cytarabine have been mentioned in the context of this disorder. Affiliated tissues include monocytes, myeloid and bone, and related phenotypes are acute monocytic leukemia and growth/size/body region

Wikipedia : 76 Acute monocytic leukemia (AMoL, or AML-M5) is considered a type of acute myeloid... more...

Description from OMIM: 151380

Related Diseases for Leukemia, Acute Monocytic

Diseases in the Monocytic Leukemia family:

Leukemia, Acute Monocytic Adult Acute Monocytic Leukemia
Chronic Monocytic Leukemia Subacute Monocytic Leukemia

Diseases related to Leukemia, Acute Monocytic via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 87)
# Related Disease Score Top Affiliating Genes
1 monocytic leukemia 30.5 KMT2A KIAA0100 KAT6A CD14
2 acute myeloid leukemia with abnormal bone marrow eosinophils inv(16)(p13q22) or t(16;16)(p13;q22) 29.7 MPO KMT2A CREBBP
3 hypoxia 29.6 KMT2A EP300 CREBBP
4 leukemia, acute myeloid 28.5 NUP98 MPO MLLT3 MLLT10 MALAT1 KMT2A
5 adult acute monocytic leukemia 12.7
6 acute monoblastic leukemia 11.9
7 leukemia 10.5
8 acute myeloid leukemia with t(8;16)(p11;p13) translocation 10.2 CREBBP KAT6A
9 lymphoma 10.1
10 sarcoma 10.1
11 histiocytosis 10.1
12 rubinstein-taybi syndrome 1 10.1 EP300 CREBBP
13 acute biphenotypic leukemia 10.1 MPO MLLT10 KMT2A
14 myeloid sarcoma 10.1 MPO KMT2A
15 human t-cell leukemia virus type 2 10.0 EP300 CREBBP
16 acute myeloid leukemia with t(9;11)(p22;q23) 10.0 KMT2A MLLT3
17 chromosome 16p13.3 deletion syndrome, proximal 10.0 EP300 KAT6A CREBBP
18 leukemia, acute lymphoblastic 10.0
19 schizophrenia 19 10.0 RBM12 EP300
20 human t-cell leukemia virus type 1 10.0 EP300 CREBBP
21 precursor t-cell acute lymphoblastic leukemia 9.9 NUP98 MPO MLLT10 KMT2A
22 langerhans cell histiocytosis 9.9
23 myelodysplastic syndrome 9.9
24 respiratory failure 9.9
25 subleukemic leukemia 9.9
26 aleukemic leukemia cutis 9.9
27 blastic plasmacytoid dendritic cell 9.9
28 dendritic cell tumor 9.9
29 germ cells tumors 9.9
30 cytomegalovirus infection 9.9
31 leukemia, chronic myeloid 9.8 NUP98 MPO KMT2A
32 hematologic cancer 9.8 NUP98 MLLT10 KMT2A EP300 CREBBP
33 hepatocellular carcinoma 9.8
34 small cell cancer of the lung 9.8
35 down syndrome 9.8
36 lung cancer 9.8
37 lymphoma, hodgkin, classic 9.8
38 nijmegen breakage syndrome 9.8
39 myelofibrosis 9.8
40 myeloma, multiple 9.8
41 neuroblastoma 9.8
42 testicular germ cell tumor 9.8
43 testicular germ cell tumor 1 9.8
44 severe combined immunodeficiency, x-linked 9.8
45 lymphoma, non-hodgkin, familial 9.8
46 aplastic anemia 9.8
47 pulmonary fibrosis and/or bone marrow failure, telomere-related, 2 9.8
48 chronic myelomonocytic leukemia 9.8
49 hematopoietic stem cell transplantation 9.8
50 hemolytic anemia 9.8

Graphical network of the top 20 diseases related to Leukemia, Acute Monocytic:



Diseases related to Leukemia, Acute Monocytic

Symptoms & Phenotypes for Leukemia, Acute Monocytic

Symptoms via clinical synopsis from OMIM:

57
Heme:
acute monocytic leukemia


Clinical features from OMIM:

151380

Human phenotypes related to Leukemia, Acute Monocytic:

32
# Description HPO Frequency HPO Source Accession
1 acute monocytic leukemia 32 HP:0004845

MGI Mouse Phenotypes related to Leukemia, Acute Monocytic:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 growth/size/body region MP:0005378 10.02 AFDN CD14 CREBBP EP300 KAT6A KMT2A
2 embryo MP:0005380 9.97 AFDN CREBBP EP300 KAT6A KMT2A MLLT3
3 hematopoietic system MP:0005397 9.86 CD14 CREBBP EP300 KAT6A KMT2A MLLT3
4 immune system MP:0005387 9.76 CD14 CREBBP EP300 KAT6A KMT2A MLLT3
5 mortality/aging MP:0010768 9.65 AFDN CD14 CREBBP EP300 KAT6A KMT2A
6 neoplasm MP:0002006 9.02 CREBBP EP300 KMT2A MLLT3 NME1

Drugs & Therapeutics for Leukemia, Acute Monocytic

Drugs for Leukemia, Acute Monocytic (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 217)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Busulfan Approved, Investigational Phase 3,Phase 2,Phase 1 55-98-1 2478
2
Cytarabine Approved, Investigational Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable 147-94-4 6253
3
Daunorubicin Approved Phase 3,Phase 2,Phase 1 20830-81-3 30323
4
Mitoxantrone Approved, Investigational Phase 3,Phase 2,Phase 1 65271-80-9 4212
5
Lenograstim Approved, Investigational Phase 3,Phase 2,Phase 1,Not Applicable 135968-09-1
6
Mesna Approved, Investigational Phase 3 3375-50-6 598
7
Cyclophosphamide Approved, Investigational Phase 3,Phase 2,Phase 1 6055-19-2, 50-18-0 2907
8
Etoposide Approved Phase 3,Phase 2,Phase 1 33419-42-0 36462
9
Idarubicin Approved Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable 58957-92-9 42890
10
Aldesleukin Approved Phase 3,Phase 2,Phase 1 85898-30-2, 110942-02-4
11
Amsacrine Approved, Investigational Phase 3 51264-14-3 2179
12
Thioguanine Approved Phase 3,Phase 1 154-42-7 2723601
13
Miconazole Approved, Investigational, Vet_approved Phase 3,Phase 2,Phase 1,Early Phase 1 22916-47-8 4189
14
Clofarabine Approved, Investigational Phase 3,Phase 2,Phase 1 123318-82-1 119182
15
Caspofungin Approved Phase 3 179463-17-3, 162808-62-0 468682 2826718
16
Fluconazole Approved, Investigational Phase 3 86386-73-4 3365
17
Decitabine Approved, Investigational Phase 3,Phase 2,Phase 1 2353-33-5 451668
18
Azacitidine Approved, Investigational Phase 3,Phase 2,Phase 1 320-67-2 9444
19
Fludarabine Approved Phase 3,Phase 2,Phase 1,Not Applicable 75607-67-9, 21679-14-1 30751
20
leucovorin Approved Phase 3,Phase 2,Phase 1 58-05-9 6006 143
21
Dexamethasone Approved, Investigational, Vet_approved Phase 3,Phase 1 50-02-2 5743
22
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 3,Phase 1 1177-87-3
23
Hydrocortisone Approved, Vet_approved Phase 3 50-23-7 5754
24
Methotrexate Approved Phase 3,Phase 2,Phase 1 59-05-2, 1959-05-2 126941
25
Hydrocortisone acetate Approved, Vet_approved Phase 3 50-03-3
26
Histamine Approved, Investigational Phase 3 51-45-6, 75614-87-8 774
27
Cyproheptadine Approved Phase 3 129-03-3 2913
28
Midostaurin Approved, Investigational Phase 3 120685-11-2 104937 9829523
29
Melphalan Approved Phase 2, Phase 3,Phase 3,Phase 1 148-82-3 4053 460612
30
Arsenic trioxide Approved, Investigational Phase 2, Phase 3,Phase 1 1327-53-3 518740
31
alemtuzumab Approved, Investigational Phase 2, Phase 3,Phase 1 216503-57-0
32
Carmustine Approved, Investigational Phase 3 154-93-8 2578
33
Hydroxyurea Approved Phase 3 127-07-1 3657
34
Tretinoin Approved, Investigational, Nutraceutical Phase 3,Phase 2,Phase 1 302-79-4 5538 444795
35
Folic Acid Approved, Nutraceutical, Vet_approved Phase 3,Phase 2,Phase 1 59-30-3 6037
36
tipifarnib Investigational Phase 3,Phase 2,Phase 1 192185-72-1 159324
37 Staurosporine Experimental Phase 3,Phase 1 62996-74-1
38 Vaccines Phase 3,Phase 1
39 Immunologic Factors Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable
40 Antimetabolites Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable
41 Antiviral Agents Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable
42 Etoposide phosphate Phase 3,Phase 2,Phase 1
43 Antineoplastic Agents, Alkylating Phase 3,Phase 2,Phase 1
44 Antineoplastic Agents, Phytogenic Phase 3,Phase 2,Phase 1
45 Alkylating Agents Phase 3,Phase 2,Phase 1
46 Peripheral Nervous System Agents Phase 3,Phase 2,Phase 1
47 Antibiotics, Antitubercular Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable
48 Anti-Bacterial Agents Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable
49 Antirheumatic Agents Phase 3,Phase 2,Phase 1
50 Topoisomerase Inhibitors Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable

Interventional clinical trials:

(show top 50) (show all 183)
# Name Status NCT ID Phase Drugs
1 Vaccine Therapy and GM-CSF in Treating Patients With Acute Myeloid Leukemia in Remission Unknown status NCT00454168 Phase 3
2 Combination Chemotherapy Followed by Bone Marrow or Peripheral Stem Cell Transplantation in Treating Patients With Acute Myelogenous Leukemia Unknown status NCT00002549 Phase 3 busulfan;cyclophosphamide;cytarabine;daunorubicin hydrochloride;etoposide;idarubicin;mesna;mitoxantrone hydrochloride
3 Gemtuzumab Ozogamicin in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia Unknown status NCT00091234 Phase 2, Phase 3 gemtuzumab ozogamicin
4 Combination Chemotherapy With or Without Monoclonal Antibody Therapy in Treating Patients With Refractory or Relapsed Acute Myelogenous Leukemia Unknown status NCT00006045 Phase 3 cytarabine;etoposide;mitoxantrone hydrochloride
5 Combination Chemotherapy, Interleukin-2, and Peripheral Stem Cell Transplant in Treating Patients With Acute Myeloid Leukemia Unknown status NCT00004128 Phase 3 busulfan;cyclophosphamide;cytarabine;daunorubicin hydrochloride;etoposide
6 Combination Chemotherapy, Biological Therapy, and Bone Marrow Transplantation in Treating Patients With Acute Myeloid Leukemia Unknown status NCT00002658 Phase 3 amsacrine;cyclophosphamide;cytarabine;daunorubicin hydrochloride;etoposide;idarubicin;mitoxantrone hydrochloride;thioguanine;tretinoin
7 Caspofungin Acetate or Fluconazole in Preventing Invasive Fungal Infections in Patients With Acute Myeloid Leukemia Who Are Undergoing Chemotherapy Completed NCT01307579 Phase 3 Caspofungin Acetate;Fluconazole
8 Combination Chemotherapy With or Without PSC 833, Peripheral Stem Cell Transplantation, and/or Interleukin-2 in Treating Patients With Acute Myeloid Leukemia Completed NCT00006363 Phase 3 cytarabine;daunorubicin hydrochloride;etoposide;valspodar;busulfan
9 Clofarabine or Daunorubicin Hydrochloride and Cytarabine Followed By Decitabine or Observation in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia Active, not recruiting NCT02085408 Phase 3 clofarabine;daunorubicin hydrochloride;cytarabine;decitabine
10 Combination Chemotherapy With or Without Valspodar in Treating Patients With Previously Untreated Acute Myeloid Leukemia Completed NCT00003190 Phase 3 cytarabine;daunorubicin hydrochloride;etoposide;valspodar
11 Combination Chemotherapy With or Without Bone Marrow Transplantation in Treating Children With Acute Myelogenous Leukemia or Myelodysplastic Syndrome Completed NCT00002798 Phase 3 asparaginase;daunorubicin hydrochloride;fludarabine phosphate;therapeutic hydrocortisone;cytarabine;idarubicin;dexamethasone;thioguanine;etoposide;methotrexate;cyclophosphamide;busulfan
12 Combination Chemotherapy in Treating Young Patients With Down Syndrome and Acute Myeloid Leukemia or Myelodysplastic Syndromes Completed NCT00369317 Phase 3 asparaginase;daunorubicin hydrochloride;cytarabine;thioguanine;etoposide
13 Combination Chemotherapy With or Without Gemtuzumab in Treating Young Patients With Newly Diagnosed Acute Myeloid Leukemia Completed NCT00372593 Phase 3 asparaginase;cytarabine;daunorubicin hydrochloride;etoposide;gemtuzumab ozogamicin;mitoxantrone hydrochloride
14 Combination Chemotherapy With or Without Filgrastim and/or Tretinoin in Treating Patients With Acute Myeloid Leukemia Completed NCT00005863 Phase 3 cytarabine;daunorubicin hydrochloride;etoposide;fludarabine phosphate;tretinoin
15 Tipifarnib in Treating Patients With Acute Myeloid Leukemia in Remission Completed NCT00093470 Phase 3 Tipifarnib
16 Cytarabine and Daunorubicin With or Without Gemtuzumab Ozogamicin in Treating Older Patients With Acute Myeloid Leukemia or Myelodysplastic Syndromes Completed NCT00121303 Phase 3 cytarabine;daunorubicin hydrochloride;gemtuzumab ozogamicin
17 Chemotherapy With or Without Gemtuzumab Ozogamicin in Treating Older Patients With Acute Myeloid Leukemia Completed NCT00052299 Phase 3 cytarabine;etoposide;gemtuzumab ozogamicin;idarubicin;mitoxantrone hydrochloride
18 Daunorubicin & Cytarabine +/- Zosuquidar inTreating Older Patients With Newly Diagnosed Acute Myeloid Leukemia or Refractory Anemia Completed NCT00046930 Phase 3 cytarabine;daunorubicin hydrochloride;zosuquidar trihydrochloride;Placebo
19 Cyproheptadine in Preventing Weight Loss in Children Receiving Chemotherapy for Cancer Terminated NCT01132547 Phase 3 cyproheptadine hydrochloride
20 Daunorubicin, Cytarabine, and Midostaurin in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia Active, not recruiting NCT00651261 Phase 3 cytarabine;daunorubicin;midostaurin;dexamethasone acetate
21 S0106 Cytarabine and Daunorubicin w/ or w/o Gemtuzumab Followed By HD Cytarabine and Either Gemtuzumab or Nothing in de Novo AML Completed NCT00085709 Phase 3 gemtuzumab ozogamicin;Cytosine arabinoside;Daunomycin
22 Combination Chemotherapy With or Without Gemtuzumab Ozogamicin or Tipifarnib in Treating Patients With Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes Completed NCT00454480 Phase 2, Phase 3 arsenic trioxide;azacitidine;busulfan;clofarabine;cytarabine;daunorubicin hydrochloride;fludarabine phosphate;gemtuzumab ozogamicin;melphalan;tipifarnib
23 Cytarabine With or Without VNP40101M in Treating Patients With Relapsed Acute Myeloid Leukemia Completed NCT00112554 Phase 3 cytarabine;laromustine
24 Combination Chemotherapy With or Without G-CSF in Treating Older Patients With Acute Myeloid Leukemia Completed NCT00002719 Phase 3 amsacrine;carmustine;cytarabine;etoposide;idarubicin;mitoxantrone hydrochloride
25 flt3L in Treating Patients With Acute Myeloid Leukemia Completed NCT00006223 Phase 3
26 Intensive Compared With Nonintensive Chemotherapy in Treating Older Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome Completed NCT00005823 Phase 3 cytarabine;daunorubicin hydrochloride;etoposide;hydroxyurea;idarubicin;mitoxantrone hydrochloride;thioguanine;tretinoin;valspodar
27 Combination Chemotherapy in Treating Children With Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome Completed NCT00002517 Phase 3 cytarabine;daunorubicin hydrochloride;dexamethasone;etoposide;idarubicin;mitoxantrone hydrochloride;thioguanine
28 Chemotherapy in Treating Children With Down Syndrome and Myeloproliferative Disorder, Acute Myelogenous Leukemia, or Myelodysplastic Syndrome Completed NCT00003593 Phase 3 asparaginase;cytarabine;daunorubicin hydrochloride;methotrexate;therapeutic hydrocortisone;thioguanine
29 High Dose Chemotherapy, Peripheral Stem Cell Transplantation, and Interleukin-2 in Treating Patients With Acute Myeloid Leukemia Completed NCT00002945 Phase 3 cyclophosphamide;cytarabine;etoposide;idarubicin;melphalan
30 Lenalidomide in Treating Older Patients With Acute Myeloid Leukemia Who Have Undergone Stem Cell Transplant Unknown status NCT02038153 Phase 1, Phase 2 Lenalidomide
31 Combination Chemotherapy Plus Biological Therapy in Treating Patients With Acute Myelogenous Leukemia Unknown status NCT00003405 Phase 2 amifostine trihydrate;bromodeoxyuridine;cytarabine;idarubicin;idoxuridine;isotretinoin;mitoxantrone hydrochloride
32 Clofarabine, Cytarabine, and Idarubicin in Treating Patients With Intermediate-Risk or High-Risk Acute Myeloid Leukemia or High-Risk Myelodysplasia Unknown status NCT00838240 Phase 1, Phase 2 clofarabine;cytarabine;idarubicin
33 VNP40101M Followed by Cytarabine in Treating Older Patients With Acute Myeloid Leukemia Unknown status NCT00354276 Phase 2 cytarabine;laromustine
34 Imatinib Mesylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia Who Have Received Chemotherapy Unknown status NCT00509093 Phase 2 imatinib mesylate
35 Monoclonal Antibody in Treating Patients With Acute Myelogenous Leukemia Unknown status NCT00006084 Phase 2
36 Combination Chemotherapy in Treating Patients With Relapsed Acute Myelogenous Leukemia Unknown status NCT00003758 Phase 2 cytarabine;idarubicin
37 Donor Stem Cell Transplant in Treating Patients With Acute Myeloid Leukemia in Remission Withdrawn NCT00101140 Phase 2 anti-thymocyte globulin;fludarabine phosphate;thiotepa
38 Bortezomib and Combination Chemotherapy in Treating Younger Patients With Recurrent, Refractory, or Secondary Acute Myeloid Leukemia Completed NCT00666588 Phase 2 idarubicin;cytarabine;bortezomib;etoposide
39 High-Dose Busulfan and High-Dose Cyclophosphamide Followed By Donor Bone Marrow Transplant in Treating Patients With Leukemia, Myelodysplastic Syndrome, Multiple Myeloma, or Recurrent Hodgkin or Non-Hodgkin Lymphoma Completed NCT01177371 Phase 2 busulfan;cyclophosphamide;methylprednisolone;methotrexate;cyclosporine
40 Donor Umbilical Cord Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies Completed NCT01093586 Phase 2 busulfan;cyclophosphamide;anti-thymocyte globulin;methylprednisolone;cyclosporine;mycophenolate mofetil
41 Idarubicin and Cytarabine With or Without Bevacizumab in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia Terminated NCT00096148 Phase 2 idarubicin;cytarabine
42 Cytarabine With or Without SCH 900776 in Treating Adult Patients With Relapsed Acute Myeloid Leukemia Completed NCT01870596 Phase 2 Cytarabine;CHK1 Inhibitor SCH 900776
43 Tipifarnib in Treating Older Patients With Acute Myeloid Leukemia Completed NCT01361464 Phase 2 Tipifarnib
44 Decitabine, Cytarabine, and Daunorubicin Hydrochloride in Treating Patients With Acute Myeloid Leukemia Active, not recruiting NCT01627041 Phase 2 Cytarabine;Daunorubicin Hydrochloride;Decitabine
45 Busulfan, Fludarabine Phosphate, and Anti-Thymocyte Globulin Followed By Donor Stem Cell Transplant and Azacitidine in Treating Patients With High-Risk Myelodysplastic Syndrome and Older Patients With Acute Myeloid Leukemia Active, not recruiting NCT01168219 Phase 2 Azacitidine;Busulfan;Fludarabine Phosphate;Methotrexate;Tacrolimus
46 Azacitidine and Gemtuzumab Ozogamicin in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia Active, not recruiting NCT00658814 Phase 2 Azacitidine;Gemtuzumab Ozogamicin
47 Tipifarnib in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia Completed NCT00027872 Phase 2 tipifarnib
48 Decitabine Followed by Idarubicin and Cytarabine in Treating Patients With Relapsed or Refractory AML and MDS Terminated NCT01607645 Phase 2 decitabine;idarubicin;cytarabine
49 Cholecalciferol in Treating Patients With Acute Myeloid Leukemia Undergoing Intensive Induction Chemotherapy Terminated NCT01521936 Phase 2
50 Choline Magnesium Trisalicylate and Combination Chemotherapy in Treating Patients With Acute Myeloid Leukemia Completed NCT02144675 Phase 2 choline magnesium trisalicylate;idarubicin;cytarabine

Search NIH Clinical Center for Leukemia, Acute Monocytic

Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Leukemia, Acute Monocytic cell therapies at LifeMap Discovery.
Stem-cell-based therapeutic approaches for Leukemia, Acute Monocytic:
NiCord�, umbilical cord blood-derived stem/progenitor cells for hemotological diseases
Embryonic/Adult Cultured Cells Related to Leukemia, Acute Monocytic:
Umbilical cord blood-derived stem cells (NiCord) PMIDs: 22198152

Cochrane evidence based reviews: leukemia, monocytic, acute

Genetic Tests for Leukemia, Acute Monocytic

Genetic tests related to Leukemia, Acute Monocytic:

# Genetic test Affiliating Genes
1 Acute Monocytic Leukemia 29

Anatomical Context for Leukemia, Acute Monocytic

MalaCards organs/tissues related to Leukemia, Acute Monocytic:

41
Monocytes, Myeloid, Bone, Bone Marrow, T Cells, B Cells, Lung

Publications for Leukemia, Acute Monocytic

Articles related to Leukemia, Acute Monocytic:

(show top 50) (show all 275)
# Title Authors Year
1
Anti-Cancerous Effect of Inonotus taiwanensis Polysaccharide Extract on Human Acute Monocytic Leukemia Cells through ROS-Independent Intrinsic Mitochondrial Pathway. ( 29382173 )
2018
2
Trisomy 6 as the sole stemline abnormality in a patient with acute monocytic leukemia: a case report. ( 29755835 )
2018
3
Dihydroartemisinin-induced apoptosis in human acute monocytic leukemia cells. ( 29435054 )
2018
4
Haemophagocytic lymphohistiocytosis occurred during induction chemotherapy in an acute monocytic leukemia patient with FLT3-ITD and DNMT3A mutations. ( 29843647 )
2018
5
Acute monocytic leukemia diagnosed by flow cytometry includes acute myeloid leukemias with weakly or faintly positive non-specific esterase staining. ( 29721252 )
2018
6
Enhanced Response of Acute Monocytic Leukemia Cells to Low-dose Cytarabine by 1,25-dihydroxyvitamin D3. ( 30074149 )
2018
7
Bone Marrow Adipocytes Facilitate Fatty Acid Oxidation Activating AMPK and a Transcriptional Network Supporting Survival of Acute Monocytic Leukemia Cells. ( 28108519 )
2017
8
Duplication of subtelomeric regions in an adult with acute monocytic leukemia with an acquired jumping translocation involving 3q13.31-qter. ( 28725672 )
2017
9
Cutaneous presentation preceding acute monocytic leukemia: A CARE-compliant article. ( 28272239 )
2017
10
Upregulation of long non-coding RNA MALAT-1 confers poor prognosis and influences cell proliferation and apoptosis in acute monocytic leukemia. ( 28713913 )
2017
11
5a89azaa892'a89deoxycytidine promotes migration of acute monocytic leukemia cells via activation of CCL2a89CCR2a89ERK signaling pathway. ( 28627644 )
2017
12
Cordycepin induces apoptosis of human acute monocytic leukemia cells via downregulation of the ERK/Akt signaling pathway. ( 28912858 )
2017
13
Characterization of an acquired jumping translocation involving 3q13.31-qter in a patient with de novo acute monocytic leukemia. ( 28625614 )
2017
14
Jab1/Csn5-Thioredoxin Signaling in Relapsed Acute Monocytic Leukemia under Oxidative Stress. ( 28270496 )
2017
15
Lineage switch from B acute lymphoblastic leukemia to acute monocytic leukemia with persistent t(4;11)(q21;q23) and cytogenetic evolution under CD19-targeted therapy. ( 28634616 )
2017
16
Polydatin Induces Apoptosis and Inhibits Growth of Acute Monocytic Leukemia Cells. ( 26616494 )
2016
17
Leukemia cutis preceding bone marrow relapse in acute monocytic leukemia. ( 27643547 )
2016
18
Hypoxia inducible factor-1a regulates a pro-invasive phenotype in acute monocytic leukemia. ( 27447550 )
2016
19
Acute Monocytic Leukemia Masquerading BehAset's Disease-Like Illness at Onset in an Elderly Female. ( 27610252 )
2016
20
Spurious Thrombocytosis Caused by Tumor Cell Lysis in a Patient with Acute Monocytic Leukemia. ( 28164618 )
2016
21
Acute monocytic leukemia masked by hemolytic anemia and sclerotic lesions. ( 27572458 )
2016
22
Histiocytic differentiation in acute monocytic leukemia. ( 26771450 )
2016
23
Knockdown of p54nrb inhibits migration, invasion and TNF-I+ release of human acute monocytic leukemia THP1 cells. ( 27108701 )
2016
24
The Successful Complete Remission Induction by Sorafenib Monotherapy in a FLT3-D835Y-Positive Patient with Refractory Acute Monocytic Leukemia. ( 27408351 )
2016
25
Suppression of NRF2-ARE activity sensitizes chemotherapeutic agent-induced cytotoxicity in human acute monocytic leukemia cells. ( 26708503 )
2016
26
Generation of a MLL-AF9-specific stem cell model of acute monocytic leukemia. ( 27185517 )
2016
27
A case of extramedullary involvement of acute monocytic leukemia that presented as obstructive jaundice. ( 26422978 )
2016
28
Nitric oxide is the key mediator of death induced by fisetin in human acute monocytic leukemia cells. ( 25973292 )
2015
29
Ara-C and anti-CD47 antibody combination therapy eliminates acute monocytic leukemia THP-1 cells in vivo and in vitro. ( 26125761 )
2015
30
Histiocytic sarcoma combined with acute monocytic leukemia: a case report. ( 26187047 )
2015
31
Autocrine motility factor receptor promotes the proliferation of human acute monocytic leukemia THP-1 cells. ( 26136223 )
2015
32
Induction with azacytidine followed by allogeneic hematopoietic stem cell transplantation in a Jehovah's Witness with acute monocytic leukemia. ( 25984306 )
2015
33
Posterior reversible encephalopathy syndrome following acute pancreatitis during chemotherapy for acute monocytic leukemia. ( 24881921 )
2014
34
Spontaneous regression of cutaneous blastic plasmacytoid dendritic cell neoplasm followed by acute monocytic leukemia evolving from myelodysplastic syndrome. ( 25447656 )
2014
35
Secondary acute monocytic leukemia positive for 11q23 rearrangement in Nijmegen breakage syndrome. ( 24619942 )
2014
36
Severe aplastic anemia preceding acute monocytic leukemia in an adult with acquired trisomy 21: A case report. ( 24396488 )
2014
37
Antiproliferative activities of lesser galangal (Alpinia officinarum Hance Jam1), turmeric (Curcuma longa L.), and ginger (Zingiber officinale Rosc.) against acute monocytic leukemia. ( 23819642 )
2013
38
Leukemia cutis in a patient with acute monocytic leukemia diagnosed simultaneously with hepatocellular carcinoma: A case study. ( 24179516 )
2013
39
Sorting, identification and enrichment of side population cells in THP-1 acute monocytic leukemia cells. ( 23450319 )
2013
40
Citrate induces apoptosis of the acute monocytic leukemia U937 cell line through regulation of HIF-1I+ signaling. ( 24064771 )
2013
41
Regulated cellular exposure to non-thermal plasma allows preferentially directed apoptosis in acute monocytic leukemia cells. ( 23400198 )
2013
42
Bryostatin 5 induces apoptosis in acute monocytic leukemia cells by activating PUMA and caspases. ( 24036350 )
2013
43
Effect of RNAi-induced down regulation of nuclear factor kappa-B p65 on acute monocytic leukemia THP-1 cells in vitro and vivo. ( 21901538 )
2012
44
Role of misfolded N-CoR mediated transcriptional deregulation of Flt3 in acute monocytic leukemia (AML)-M5 subtype. ( 22514634 )
2012
45
Leukemic manifestation of blastic plasmacytoid dendritic cell neoplasm lacking skin lesion : a borderline case between acute monocytic leukemia. ( 23037626 )
2012
46
A parasite rescue and transformation assay for antileishmanial screening against intracellular Leishmania donovani amastigotes in THP1 human acute monocytic leukemia cell line. ( 23299097 )
2012
47
Jumping translocations of 3q21 in an acute monocytic leukemia (M5) patient reveal mechanisms of multistage telomere shortening in pathogenesis of AML. ( 21983177 )
2012
48
Heterogeneous leukemic clones identified by NPM1 mutation analysis in patient with acute monocytic leukemia. ( 22035378 )
2012
49
Fatal bronchial invasion of Scopulariopsis brevicaulis in an acute monocytic leukemia patient. ( 22633337 )
2012
50
Mutations inDNMT3A and loss of RKIP are independent events in acute monocytic leukemia. ( 22875620 )
2012

Variations for Leukemia, Acute Monocytic

Copy number variations for Leukemia, Acute Monocytic from CNVD:

7 (show all 23)
# CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 21832 1 16200000 20400000 Gain Acute monocytic leukemia
2 31525 1 28000000 30200000 Gain Acute monocytic leukemia
3 61776 12 10100000 12800000 Loss Acute monocytic leukemia
4 90243 15 20700000 25700000 Gain Acute monocytic leukemia
5 93369 15 52900000 59100000 Gain Acute monocytic leukemia
6 108855 17 23200000 28800000 Deletion NF1 Acute monocytic leukemia
7 110292 17 31800000 38100000 Gain Acute monocytic leukemia
8 116498 17 67100000 70900000 Loss Acute monocytic leukemia
9 125458 19 13900000 20000000 Gain Acute monocytic leukemia
10 133734 19 6900000 13900000 Gain Acute monocytic leukemia
11 140901 2 203300000 204900000 Loss Acute monocytic leukemia
12 188152 4 59500000 66600000 Loss Acute monocytic leukemia
13 190404 4 88000000 93700000 Loss Acute monocytic leukemia
14 191655 5 1 4500000 Gain Acute monocytic leukemia
15 196530 5 168500000 172800000 Gain Acute monocytic leukemia
16 201329 5 68400000 73300000 Gain Acute monocytic leukemia
17 206333 6 139000000 142800000 Loss Acute monocytic leukemia
18 219029 7 121100000 123800000 Loss Acute monocytic leukemia
19 224721 7 37200000 43300000 Loss Acute monocytic leukemia
20 226783 7 61700000 67000000 Loss Acute monocytic leukemia
21 226785 7 61700000 77500000 Loss Acute monocytic leukemia
22 243519 8 84600000 86900000 Gain Acute monocytic leukemia
23 250024 9 19900000 25600000 Loss Acute monocytic leukemia

Expression for Leukemia, Acute Monocytic

Search GEO for disease gene expression data for Leukemia, Acute Monocytic.

Pathways for Leukemia, Acute Monocytic

GO Terms for Leukemia, Acute Monocytic

Cellular components related to Leukemia, Acute Monocytic according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 nucleoplasm GO:0005654 9.61 AFDN CREBBP EP300 KAT6A KMT2A MLLT10
2 histone acetyltransferase complex GO:0000123 8.8 CREBBP EP300 KAT6A

Biological processes related to Leukemia, Acute Monocytic according to GeneCards Suite gene sharing:

(show all 11)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of transcription, DNA-templated GO:0045893 9.72 CREBBP EP300 KAT6A KMT2A MLLT3
2 rhythmic process GO:0048511 9.54 CREBBP EP300 KMT2A
3 histone H4 acetylation GO:0043967 9.49 EP300 KAT6A
4 beta-catenin-TCF complex assembly GO:1904837 9.48 CREBBP EP300
5 positive regulation of transforming growth factor beta receptor signaling pathway GO:0030511 9.46 CREBBP EP300
6 regulation of transcription from RNA polymerase II promoter in response to hypoxia GO:0061418 9.43 CREBBP EP300
7 histone acetylation GO:0016573 9.43 CREBBP EP300 KAT6A
8 positive regulation of transcription of Notch receptor target GO:0007221 9.4 CREBBP EP300
9 N-terminal peptidyl-lysine acetylation GO:0018076 9.16 CREBBP EP300
10 positive regulation of type I interferon production GO:0032481 9.13 CD14 CREBBP EP300
11 protein acetylation GO:0006473 8.8 CREBBP EP300 KAT6A

Molecular functions related to Leukemia, Acute Monocytic according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 transcription coactivator activity GO:0003713 9.62 CREBBP EP300 KAT6A NUP98
2 transferase activity, transferring acyl groups GO:0016746 9.61 CREBBP EP300 KAT6A
3 chromatin binding GO:0003682 9.55 CREBBP EP300 MLLT10 MLLT3 MPO
4 histone binding GO:0042393 9.54 KAT6A MLLT10 MLLT3
5 histone acetyltransferase activity GO:0004402 9.43 CREBBP EP300 KAT6A
6 lysine-acetylated histone binding GO:0070577 9.4 KMT2A MLLT3
7 peptide N-acetyltransferase activity GO:0034212 8.96 CREBBP EP300
8 acetyltransferase activity GO:0016407 8.8 CREBBP EP300 KAT6A

Sources for Leukemia, Acute Monocytic

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....